Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) had its price target lifted by investment analysts at Guggenheim from $115.00 to $130.00 in a report released on Wednesday,Benzinga reports. Get Spyre Therapeutics alerts:Get Our Latest Analysis on SYRESpyre Therapeutics Stock PerformanceShares of NASDAQ SYRE opened at $103.85 on Wednesday. Spyre Therapeutics has a 52-week low of $14.51 and a 52-week high of $108.14. Insider Buying and SellingIn other Spyre Therapeutics news, insider Sheldon Sloan sold 8,334 shares of Spyre Therapeutics stock in a transaction dated Wednesday, July 1st. Further ReadingReceive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.